Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
Release Date: November 30, 2020
Expiration Date: November 30, 2021
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The treatment of transplant-ineligible patients with newly diagnosed myeloma remains a clinical challenge, but recent developments in novel therapeutic approaches have been shown to improve outcomes in these patients. In this activity, Dr. Usmani reviews the key clinical data in transplant-ineligible, newly diagnosed myeloma, and provides evidence-based recommendations for choosing individualized treatment regimens.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Choose optimal therapeutic regimens based on specific patient- and disease-related characteristics
- Employ current guidelines and evolving data from trials evaluating novel multi-drug combinations in the frontline setting
- Identify and manage treatment-emergent adverse events associated with treatment approaches in the frontline setting
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma – Saad Z. Usmani, MD, FACP
Instructions for Participation and Credit
This activity is eligible for credit through November 30, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Saad Z. Usmani, MD, FACP
Division Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani joined the Levine Cancer Institute faculty in July 2013; he also currently holds an academic appointment as Clinical Professor of Medicine at the University of North Carolina-Chapel Hill School of Medicine.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and is a fellow of the American College of Physicians. He holds membership in several professional societies, including the International Myeloma Working Group (IMWG), SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation (ASBMT). Dr. Usmani has served as the Track Leader on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and he is a member of the ASH Committee on Plasma Cell Neoplasia and the National Cancer Institute Myeloma Steering Committee. He is on the editorial review board of numerous medical journals, and has authored/co-authored more than 150 peer-reviewed research manuscripts and 200 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani’s research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-039-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Saad Usmani has received honoraria related to speakers’ bureau activities from Celgene Corporation − A Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Sanofi, and Takeda Oncology, as well as formal advisory activities from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, GlaxoSmithKline plc, Janssen, Merck & Co., Inc., Sanofi, Seattle Genetics, Inc., Skyline Diagnostics B.V., and Takeda Oncology. He has received grant support related to research activities from Amgen, Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Inc., Sanofi, Skyline Diagnostics, Seattle Genetics, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology./p>
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.